ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NRIX vs VRDN // RETURN ON INVESTED CAPITAL (ROIC)

Nurix Therapeutics Inc. (NASDAQ) VS. Viridian Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: NRIX 3 — VRDN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NRIX VS. VRDN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NRIX VRDN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -8.89% -9.85% +0.96 NRIX /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 54.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 9.52 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 NRIX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 65.6 70.4 -4.80 VRDN /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.96B $2.81B $153.2M NRIX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NRIX REV VRDN REV NRIX GROSS % VRDN GROSS % NRIX FCF VRDN FCF
FY 2025 $84.0M $0 — — -$263.5M -$276.9M
FY 2024 $54.5M $0 — — -$181.9M -$232.8M
FY 2023 $77.0M $0 — — -$81.4M -$184.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NRIX // BETA —
VRDN // BETA —